Topics

breakthrough cases

"... an instance in which a person becomes sick with a disease despite having received the vaccine for that disease. In other words, the vaccine fails to prevent the person from becoming infected."

Source:  https://www.dictionary.com/e/tech-science/breakthrough-case/

552 Fully Vaccinated Oregon Residents Died Of COVID-19, Half Received Pfizer Vaccine
Age-associated SARS-CoV-2 breakthrough infection and changes in immune response in a mouse model
An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam
An outbreak caused by the SARS-CoV-2 Delta variant (B.1.617.2) in a secondary care hospital in Finland, May 2021
Appendix 1: estimation of number needed to vaccinate to prevent a COVID-19 hospitalisation for primary vaccination, booster vaccination (3rd dose), autumn 2022 and spring 2023 booster for those newly in a risk group
Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Commentary from Dr. David Bauer of the Francis Crick Institute
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections
Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence
Compilation of Donald Trump promoting COVID-19 vaccines
Correlation of SARS-CoV-2 Breakthrough Infections to Time-from-vaccine; Preliminary Study
Correspondence: Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021
COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May – November 2021
COVID-19 cases with Lineage B.1.1.529 (Omicron) or S-Gene Target Failure (SGTF) in Ontario: October 31, 2021 to December 29, 2021
COVID-19 in Northern Ireland: Vaccination Status of Deaths and Hospitalisations — Updated to Include Weeks 51 to 2 (20th December 2021 to 16th January 2022)
COVID-19 Monitor: COVID-19 cases, variants, vaccines, hospitalisations and deaths
Covid-19 Rapport om omikronvarianten
COVID-19 vaccinations data
COVID-19 Vaccine Breakthrough Case Investigation and Reporting
COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021
Covid-19 Vaccine Mandates Are Now Pointless: Covid-19 vaccines do not keep people from catching the prevailing Delta variant and passing it to others
COVID-19 vaccine safety update: Primary series in young children and booster doses in older children and adults
COVID-19 vaccine surveillance report, Week 13
COVID-19 vaccine surveillance report, Week 2
COVID-19 vaccine surveillance report, Week 42
COVID-19 vaccine surveillance report, Week 43
COVID-19 vaccine surveillance report, Week 44
COVID-19 vaccine surveillance report, Week 48
COVID-19 vaccine surveillance report, Week 5 2022
COVID-19 Weekly Surveillance in NSW: Epidemiological Week 52 ending 1 January 2022
Covid-19: Fully vaccinated people can carry as much delta virus as unvaccinated people, data indicate
COVID-19: stigmatising the unvaccinated is not justified
Dataset: Deaths occurring between 1 January 2021 and 31 May 2022 edition of this dataset
Does the FDA think these data justify the first full approval of a covid-19 vaccine?
Dr. Peter McCullough presentation at 78th Annual Meeting of Association of American Physicians and Surgeons (AAPS)
Dr. Robert Redfield’s shocking admission about vaccine deaths
Dr. Scott Youngblood presentation to the San Diego City Council
Durability of immune responses to the BNT162b2 mRNA vaccine
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022
Effectiveness of COVID-19 vaccines against Omicron or Delta infection
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study
Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 Omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study
764